Dupilumab-induced psoriasiform dermatitis in two pediatric cardiac transplant patients.
Trevor LockardSarah A MullenErica B LeeHana NieburNicole HarterPublished in: Pediatric dermatology (2023)
Dupilumab is an interleukin-4 receptor antagonist important in the treatment of refractory atopic dermatitis (AD), particularly among pediatric patients. Two boys with a history of AD and cardiac transplant who developed psoriasiform dermatitis in response to dupilumab therapy are reported. These patients paradoxically developed an immune-mediated adverse drug reaction despite taking systemic immunosuppressive agents. While the literature suggests possible pathomechanisms for psoriasiform dermatitis despite immunosuppression, further research is necessary to better characterize this unique and unexpected phenomenon.
Keyphrases
- atopic dermatitis
- end stage renal disease
- ejection fraction
- newly diagnosed
- adverse drug
- systematic review
- left ventricular
- prognostic factors
- emergency department
- peritoneal dialysis
- stem cells
- oxidative stress
- drug induced
- endothelial cells
- electronic health record
- diabetic rats
- smoking cessation
- patient reported
- stress induced